Analyst Research Report Snapshot

Title:

Aurobindo Pharma (ARBP) - Qtr. Update - Dated - June 02, 2014

Price:

$35.00

Provider:

Axis Capital Limited

Date:

02 Jun 2014

Pages:

4

Type:

AcrobatPDF

Companies referenced:

ARBN.NS

Available for Immediate Download
Summary:

Aurobindo Pharma’s (Bloomberg: ARBP IN) Q4 performance was much ahead of our/ Street estimate. Revenue (up 48% YoY, Rs 23 bn) was marginally above estimate. This was driven by US formulations (Rs 11 bn vs. Rs 10 bn estimated) due to better pricing, market share in gCymbalta. EBITDA margin (32% vs. our/ Street estimate: 27%/ 29%) was a positive surprise. Even ex-gCymbalta (assuming USD 45 mn revenue; 75% margin), EBITDA margin was >26%. Margin expansion was led by operating leverage and improving product mix. Consequently, adj. PAT at Rs 4.7 bn (4x Q4FY13) was above estimate (our/ Street: Rs 4 bn). Maintain HOLD with TP of Rs 575 (10% downside from CMP) Maintain HOLD with TP of Rs 575 (11x FY16E EPS). Faster turnaround of Actavis business and debt reduction could trigger rerating. At CMP of Rs 639, the stock trades at 15x FY15E EPS of Rs 42 and 12x FY16E EPS of Rs 52. Key highlights  Revenue growth led by: (a) US (Rs 11 bn, up 130% YoY driven by currency benefits, injectables, re-launch of Cephalosporins, and ramp-up of recent launches including gCymbalta), and (b) EU (up 77% YoY driven by customer addition and product launches). API revenue was up 13% YoY to Rs 7.5 bn  Gross margin improved 340 bps YoY/ 1,270 bps QoQ to 61% largely due to gCymbalta. Ex-gCymbalta, gross was ~60% (assuming 75% gross margin on gCymbalta)  ARBP filed 28 ANDAs (336 cumulative) and received 1 final approvals in Q4FY14  Management confident of maintaining base-EBITDA (ex-Cymbalta, ex-Actavis business) margin of >23% (in line with Q2FY14). Actavis business (~USD430 mn) is currently making EBITDA margin loss of 6%; management remains confidant of turning EBITDA neutral in FY17. Our FY15E EBITDA margin of 17% factors in 23% base-EBITDA margin and 3% EBITDA margin loss for Actavis business Regards, Deepak Khetan (VP – Life Sciences) deepak.khetan@axiscap.in; 91 22 4325 1132

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.